Allergan Inc. v. Apotex Inc., 2022 FC 260
| Jurisdiction | Federal Jurisdiction (Canada) |
| Citation | 2022 FC 260 |
| Court | Federal Court (Canada) |
| Date | 23 February 2022 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
3 practice notes
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...patent context: Novo Nordisk Canada Inc v Cobalt Pharmaceuticals Inc, 2010 FC 746 [Novo Nordisk] and Allergan Inc v Apotex Inc, 2022 FC 260 [174] In Novo Nordisk, the patent in dispute (851 Patent) claimed the S-enantiomer of a compound (repaglinide), its use for the treatment of Type 2 d......
-
Canadian Patent Law 2022: A Year In Review
...invention. This is often achieved by reciting the claimed product is "for use" in a particular manner. In Allergan Inc v Apotex Inc,2022 FC 260, the Federal Court construed a claim reciting "An oral dosage form of a bisphosphonate for use with or without food or beverage intake" as being di......
-
Federal Court Finds Formulation Patent Relating To ACTONEL DR Valid But Not Infringed
...Patented Medicines (Notice of Compliance) Regulations relating to risedronate sodium (Allergan's ACTONEL DR): Allergan Inc v Apotex Inc, 2022 FC 260. Justice Kane found Canadian Patent No. 2,602,188 (the 188 patent) valid but not The 188 patent relates to a dosage form of a bisphosphonate, ......
2 firm's commentaries
-
Canadian Patent Law 2022: A Year In Review
...invention. This is often achieved by reciting the claimed product is "for use" in a particular manner. In Allergan Inc v Apotex Inc,2022 FC 260, the Federal Court construed a claim reciting "An oral dosage form of a bisphosphonate for use with or without food or beverage intake" as being di......
-
Federal Court Finds Formulation Patent Relating To ACTONEL DR Valid But Not Infringed
...Patented Medicines (Notice of Compliance) Regulations relating to risedronate sodium (Allergan's ACTONEL DR): Allergan Inc v Apotex Inc, 2022 FC 260. Justice Kane found Canadian Patent No. 2,602,188 (the 188 patent) valid but not The 188 patent relates to a dosage form of a bisphosphonate, ......